DOLORES REMEDIOS
SERRANO LÓPEZ
Profesora titular de universidad
![Foto de DOLORES REMEDIOS](/img/nophoto.png)
![Foto de Universidad CEU Cardenal Herrera](/img/noimage_org.png)
Universidad CEU Cardenal Herrera
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Universidad CEU Cardenal Herrera (18)
2023
-
Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers
International journal of pharmaceutics, Vol. 635, pp. 122788
2022
-
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
Pharmaceutics, Vol. 14, Núm. 9
2020
-
Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis
Molecules, Vol. 25, Núm. 6
-
Nucleotides and AHCC Enhance Th1 Responses in Vitro in Leishmania-Stimulated/Infected Murine Cells
Molecules, Vol. 25, Núm. 17
-
Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis
International Journal of Pharmaceutics, Vol. 588
-
Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases
ACS Infectious Diseases, Vol. 6, Núm. 10, pp. 2647-2660
2019
-
Technology-enhanced learning in higher education: How to enhance student engagement through blended learning
European Journal of Education, Vol. 54, Núm. 2, pp. 273-286
2018
-
Applying loop-mediated isothermal amplification (LAMP) in the diagnosis of malaria, leishmaniasis and trypanosomiasis as point-of-care tests (POCTs)
Current Topics in Medicinal Chemistry, Vol. 18, Núm. 16, pp. 1358-1374
-
New drugs and therapeutic/diagnostic targets for fungal and parasitic diseases - part I
Current Topics in Medicinal Chemistry
-
New drugs and therapeutic/diagnostic targets for fungal and parasitic diseases - part II
Current Topics in Medicinal Chemistry
-
Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 124, pp. 13-27
-
Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis
Molecular Pharmaceutics, Vol. 15, Núm. 7, pp. 2570-2583
2017
-
Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections
Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106
-
Engineering synergistically active and bioavailable cost-effective medicines for neglected tropical diseases; the role of excipients
Current Topics in Medicinal Chemistry, Vol. 17, Núm. 25, pp. 2888-2900
2016
-
Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine/4-aminosalicylic acid cocrystals
European Journal of Pharmaceutical Sciences, Vol. 89, pp. 125-136
2015
-
Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles
Molecular Pharmaceutics, Vol. 12, Núm. 2, pp. 420-431
2014
-
New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp
International Journal of Pharmaceutics, Vol. 473, Núm. 1-2, pp. 148-157
2013
-
Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations
International Journal of Pharmaceutics, Vol. 447, Núm. 1-2, pp. 38-46